Research ArticleArticle
Short-term Risk of Total Malignancy and Nonmelanoma Skin Cancers with Certolizumab and Golimumab in Patients with Rheumatoid Arthritis: Metaanalysis of Randomized Controlled Trials
Pierre Le Blay, Gael Mouterde, Thomas Barnetche, Jacques Morel and Bernard Combe
The Journal of Rheumatology March 2012, jrheum.110982; DOI: https://doi.org/10.3899/jrheum.110982
Pierre Le Blay
Gael Mouterde
Thomas Barnetche
Jacques Morel
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Short-term Risk of Total Malignancy and Nonmelanoma Skin Cancers with Certolizumab and Golimumab in Patients with Rheumatoid Arthritis: Metaanalysis of Randomized Controlled Trials
Pierre Le Blay, Gael Mouterde, Thomas Barnetche, Jacques Morel, Bernard Combe
The Journal of Rheumatology Mar 2012, jrheum.110982; DOI: 10.3899/jrheum.110982
Short-term Risk of Total Malignancy and Nonmelanoma Skin Cancers with Certolizumab and Golimumab in Patients with Rheumatoid Arthritis: Metaanalysis of Randomized Controlled Trials
Pierre Le Blay, Gael Mouterde, Thomas Barnetche, Jacques Morel, Bernard Combe
The Journal of Rheumatology Mar 2012, jrheum.110982; DOI: 10.3899/jrheum.110982